CytoSorbents Corporation (CTSO)

[caesare74]

Significant growth and sustainable move in pps will happen when (I) Switzerland gets the "medical code" (Jan. 2019), Austria (expected sometimes in 2019) and further countries e.g. where there is a partnerhsip with FMC in place. The three countires, Germany, Switzerland and Autstria, this will accelerate not only the sales, but also will have a positive impact in other countries where the medical code is not yet avaiable. Local partnships, e.g. Italy and especially Japan with Terumo should pay off in 2019. (II) a partnership with a big pharma is announced, e.g. Novartis (influcence of Dr. Carl June), (III) FDA approval.

Bertha: I also expect that Cytosorb will have a pre-annoucement earl 2019 about the fiscal year 2018.

IMO there will be three big annoucements in Jan. 2019: partnership, 2018 results and capital increase. As said earlier, CTSO needs a larger cap. base to accelerate the sales. But I would see this very positive since we will gain a broader investor base and faster sales increase. Cytosorb needs to convert the huge market potential much quicker. We are still ahead of any competition - but this won't last for ever.